德适生物将赴港上市，染色体核型分析领域市占率第一

Core Viewpoint - The company, Deshi Biotechnology, has submitted a second listing application to the Hong Kong Stock Exchange, marking a significant step in its journey towards going public after receiving regulatory approval [1][10]. Group 1: Company Overview - Deshi Biotechnology is recognized as a "national specialized and innovative small giant" in the field of chromosome karyotype analysis, achieving the highest market share in China [1][7]. - The company has developed a fully automated cell laboratory workflow that significantly enhances the accuracy of chromosome karyotype analysis to over 99%, addressing long-standing clinical challenges in the industry [3][6]. Group 2: Industry Context - Chromosome karyotype analysis is crucial for diagnosing various genetic disorders, including Down syndrome and certain blood cancers, but has historically faced issues with accuracy and lengthy reporting times [2]. - The market for chromosome karyotype analysis has been dominated by international giants like Carl Zeiss and Leica, which hold over 95% of the market share [3]. Group 3: Financial Performance - In 2024, Deshi Biotechnology achieved a market share of 30.6% in the chromosome karyotype analysis sector, surpassing international competitors [7]. - The company's revenue for the first three quarters of 2025 reached 112 million RMB, a 470% increase compared to 19.59 million RMB in the same period of 2024, with a gross margin of 75.9% [7][8]. - As of September 30, 2025, the company had cash and cash equivalents totaling 250 million RMB, indicating strong market recognition and the ability to convert technological advantages into commercial success [7].